BOTANIX PHARMACEUTICALS LTD — Investor Presentation 2017

Jul 10, 2017

==> picture [166 x 74] intentionally omitted <==

ASX/Media Release

11 July 2017

Non-Deal Roadshow Presentation

Sydney, 11 July 2017 : Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) is pleased to release a new corporate overview, to be presented to investors as part of a non-deal roadshow across Australia in the coming weeks.

This investor presentation is being used to provide an update on the Company’s key activities including its rapid operational progress over the first 12 months since listing on ASX, its lead clinical development program (BTX 1503) for acne and recently generated Phase 1a results, plans for progressing BTX1503 rapidly into patient studies in the coming months, development of other pipeline products, as well as key milestones planned for the near to medium term.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals is a clinical stage medical dermatology company, which is dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed, or are treated with therapeutics that are burdened with side effects profiles. Botanix is harnessing the untapped potential of a synthetic active pharmaceutical ingredient, known as cannabidiol, which has a wellestablished safety profile. Botanix has successfully completed its first-in-man studies with BTX 1503 and is preparing to conduct a follow-on clinical trial with acne patients in 2H 2017. The Company has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases and plans to progress the development of BTX 1503 for acne and its pipeline of other Permetrex[TM] enabled products alone, or in collaboration with partners.

For more information on Botanix, please visit www.botanixpharma.com or follow us on Twitter @Botanixpharma.

For more information, please contact:

General enquiries

Matt Callahan Botanix Pharmaceuticals Ltd Executive Director P: +1 215 767 4184 E: mcallahan@botanixpharma.com

Investor Relations Joel Seah Vesparum Capital P: +61 3 8582 4800 E: botanixpharma@vesparum.com

Media enquiries

Harrison Polites MC Partners P: +61 409 623 618 E: Harrison.polites@mcpartners.com.au

==> picture [138 x 154] intentionally omitted <==

==> picture [215 x 318] intentionally omitted <==

Non-Deal Roadshow Investor Presentation July 2017

+

==> picture [79 x 27] intentionally omitted <==

Investment highlights

Botanix is one of the most compelling emerging companies on the ASX

Dermatology Focused

▪ Targeting a multi-billion dollar market for acne treatments with no new products approved in the last 20 years

▪ Not typical biotech – much faster development pathway for dermatology products, drives lower costs and much quicker timeline to approval

Novel Approach

• Lead products based on synthetic form of cannabidiol - greatly enhances the probability of clinical and regulatory success

▪ Exclusive global rights to use Permetrex[TM] delivery technology for all skin diseases, with potential to deliver near term deals and revenues

Experienced Team

• Predominantly US based leadership team with 20+ FDA approvals between them

▪ Advanced lead product from formulation to successful clinical trials within 12 months and created 5 new products using Permetrex[TM] technology

Botanix Pharmaceuticals Ltd.

2

+

==> picture [79 x 27] intentionally omitted <==

Corporate overview

Medical dermatology company with a clear path to commercialisation and a highly aligned Board and management team

Trading information

Share price performance

Share price (7-Jul-17)	A$0.046
52 week low / high	A$0.026 / A$0.075
Shares outstanding1,2	543.1
Market capitalisation	A$25.0m
Cash (as at 31-Mar-17)2	A$8.9m
Debt (as at 31-Mar-17)	Nil
Enterprise value	A$16.1m

==> picture [350 x 296] intentionally omitted <==

----- Start of picture text -----

Share price (A$) Volume (m)
0.08 100
0.06 75
0.04 50
0.02 25
- -
Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17
Volume (RHS) BOT S&P/ASX 300 Health Care Index
----- End of picture text -----

Top shareholders (as at July 2017)

Top shareholders (as at July 2017)
Shareholder	%
Matthew Callahan –Executive Director	13.0
Caperi Pty Ltd –Co-founder	13.0
Board and management (excl. shareholders above)	3.0

Source: IRESS

Botanix Pharmaceuticals Ltd.

3

1. Includes 156.5m fully paid ordinary shares subject to escrow until 15 July 2018 2. Include recently completed placement (A$7.4m). Excludes 47.9m unlisted options with exercise price range of A$0.03 - A$0.07 and expiry date range of Jan 2018 to May 2020

+

==> picture [79 x 27] intentionally omitted <==

Senior leadership: track record of success

Proven industry professionals with experience in rapid development of pharmaceuticals

	Mr Matthew Callahan corporate + IP	20+ FDA approved
	Executive Director ▪ Developed3 products to date that have received FDA approval, 1 pending approval	products
	▪ Previous investment director of 2 venture capital firms investing in life sciences
	Dr Bill Bosch manufacturing + IP
	Executive Director
	▪ 6 FDA approved productsand inventor of the iCeutica SoluMatrix Technology
	▪ Founder of NanoSystems and co-inventor of drug delivery technology NanoCrystal
	Dr Michael Thurn ops + regulatory
	Chief Operating Officer
	▪ Extensive start up life sciences experience across a range of technology platforms
	▪ Previous MD of Spinifex Pharmaceutical, which sold to Novartis for A$700m
	Mr Mark Davis regulatory + clinical
	VP Clinical and regulatory
	▪ 30 years clinical experience with19 FDA approved products across dermatology
	▪ Former clinical lead with Medicis and Connetics and FDA experience with cannabidiol

Botanix Pharmaceuticals Ltd.

4

+

==> picture [79 x 27] intentionally omitted <==

Multiple near term milestones from pipeline

De-risked pipeline of dermatology products, with deals on the Permetrex [TM] technology to augment revenue and news flow in the near term

	Product Candidate	Product Candidate	Indication	Pre-Clin	Phase 1	Phase 2	Next Milestones
	Synthetic Cannabidiol	BTX 1503	Moderate to Severe Acne				Phase 1b Acne Patient Study Start Q3 CY2017
		BTX 1204	Atopic Dermatitis				Phase 1b AD Patient Study Start Q4 CY2017
		BTX 1308	Psoriasis				Pre-clinical formulation Q4 CY2017
	PermetrexTM Enabled	BTX 1701	Acne Cleanser				Patient study start Q4 CY2017
		BTX 1801	Not disclosed				Formulation complete Q3 CY2017

Botanix Pharmaceuticals Ltd.

5

+

==> picture [79 x 27] intentionally omitted <==

Why are we focused first on acne?

Global prescription market expected to grow to >US$4.5bn by 2018 and is only a subset of the global dermatology opportunity

Global prescription acne product revenues (topical Annual topical prescription acne product revenues and oral treatments)

==> picture [659 x 173] intentionally omitted <==

----- Start of picture text -----

Value of the global acne prescription market is expected to Top branded acne products containing only generic drugs have
reach US$4.5bn by 2018 [1] achieved revenues of up to >US$300m p.a. [2]
$331
US$4,530m 2011
$285
2012
$199 2013
US$3,951m $175 $168 $167
US$3,845m
$95
$85
2012 2013 2018 Epiduo Aczone Tazorac Differin Acanya Ziana Benzaclin Atralin
(Galderma) (Allergen) (Allergen) (Galderma) (Valeant) (Valeant) (Valeant) (Valeant)
(Valeant)
----- End of picture text -----

Large demand with limited recent product development

▪ 50 million patients (in the US alone) used an acne product in 2015

▪ No new chemical entities have been approved by the FDA in the last 20 years for the treatment of acne

▪ Only “new” products launched were combinations of old drugs in new formulations or packaging

1. BCC Research, May 2013. Skin Disease Treatment and Global Markets 2. Symphony Health Solutions, Pharmaceutical Audit Suite for 2012 as reported in Demira S1

Botanix Pharmaceuticals Ltd.

6

+

==> picture [79 x 27] intentionally omitted <==

How does BTX 1503 work to treat acne?

BTX 1503 utilises synthetic cannabidiol combined with a novel skin delivery technology

==> picture [626 x 338] intentionally omitted <==

----- Start of picture text -----

Attacks P. Acnes Reduces
bacteria Inflammation
Switches off excess Retards formation
production of of sebum “plugs”
sebum
----- End of picture text -----

Source: Cannabidiol exerts sebostatic and anti inflammatory effects on human sebocytes (2014).The Journal of Clinical Investigation

Botanix Pharmaceuticals Ltd.

7

+

==> picture [79 x 27] intentionally omitted <==

BTX 1503 Phase 1a clinical trial results

BTX 1503 utilises synthetic cannabidiol combined with a novel skin delivery technology

Safety, Tolerability and Irritation

Effective delivery into and deposition in the skin

• BTX 1503 displayed an excellent safety profile

• Little to no evidence of skin irritation observed across all dose levels

• No severe adverse events recorded and the incidence of other adverse events was very low

• Most common adverse event was mild dryness - consistent with the mechanism of action of BTX 1503

==> picture [307 x 250] intentionally omitted <==

----- Start of picture text -----

Permetrex™
+
Synthetic
Cannabidiol
EPIDERMIS
----- End of picture text -----

Source: Cannabidiol exerts sebostatic and anti inflammatory effects on human sebocytes (2014).The Journal of Clinical Investigation

Botanix Pharmaceuticals Ltd.

8

+

==> picture [79 x 27] intentionally omitted <==

BTX 1503 key advantage 1: synthetic material

Use of synthetic cannabidiol greatly increases the chance of clinical success and regulatory approval - at a much lower COGS than naturally extracted material

==> picture [113 x 38] intentionally omitted <==

Synthetic cannabidiol Naturally extracted cannabidiol 1 chemical 100+ chemicals Multiple impurities 100% pure (anything above 0.05% needs to be identified and tested) Scaled up to 50kg Scaled up to <1kg Must comply with FDA’s No additional “Botanical Drug Development compliance required Guidance for Industry” [1]

==> picture [161 x 121] intentionally omitted <==

1. Botanical Drug development – Guidance for Industry. FDA

Botanix Pharmaceuticals Ltd.

9

+

==> picture [79 x 27] intentionally omitted <==

BTX 1503 key advantage 2: drug delivery

Permetrex[TM] technology drives synthetic cannabidiol directly into the skin – oral administration only delivers ~6% to the blood

With Permetrex™

Unmodified Drug Epidermis Dermis

==> picture [49 x 50] intentionally omitted <==

==> picture [49 x 47] intentionally omitted <==

==> picture [35 x 36] intentionally omitted <==

==> picture [27 x 25] intentionally omitted <==

==> picture [31 x 53] intentionally omitted <==

==> picture [23 x 22] intentionally omitted <==

==> picture [22 x 22] intentionally omitted <==

==> picture [22 x 22] intentionally omitted <==

==> picture [57 x 23] intentionally omitted <==

==> picture [57 x 23] intentionally omitted <==

==> picture [58 x 23] intentionally omitted <==

==> picture [57 x 23] intentionally omitted <==

==> picture [57 x 23] intentionally omitted <==

==> picture [57 x 23] intentionally omitted <==

==> picture [57 x 23] intentionally omitted <==

==> picture [21 x 21] intentionally omitted <==

==> picture [32 x 37] intentionally omitted <==

==> picture [32 x 37] intentionally omitted <==

==> picture [32 x 37] intentionally omitted <==

==> picture [32 x 37] intentionally omitted <==

==> picture [32 x 37] intentionally omitted <==

==> picture [32 x 37] intentionally omitted <==

Botanix holds the exclusive rights to utilise Permetrex[TM] for all drugs that treat skin diseases

Botanix Pharmaceuticals Ltd.

10

+

==> picture [79 x 27] intentionally omitted <==

BTX 1503 market positioning

BTX 1503 has the potential to be the market leading product for acne treatment with no undesirable side effects

Market landscape for acne treatments[1]

• BTX 1503 has multiple mechanisms of action that directly treat the key pathogenic factors causing acne, making it a potentially superior treatment to existing therapies

• While systematic therapies (i.e. oral isotretinoin) may inhibit sebum (skin-oil) production, its use is limited by very serious side-effects

• Significant unmet need for an effective therapy that targets the cause of acne (i.e. sebum production) and does not have the undesirable side effects associated with traditional acne treatments

• Significant market opportunity; major existing treatments fetched annual revenues in the range of US$700m-US$800m when they were patented products

• BTX 1503’s patent protection is a significant competitive advantage, as all other treatments below are now generic products

Method of action	BTX 1503	Clindamycin	Tretinoin	Adapalene	Minocycline	Erythromycin	Accutane
Reduces excessive sebum (skin oil) production	✓						✓
Anti-inflammatory	✓		✓	✓			✓
Anti-bacterial	✓	✓			✓	✓	✓
Topical (applied to a specific area of the body)	✓		✓	✓
Minimal side effects	✓		✓	✓		✓
Patent protected (not a generic product)	✓

1. Subject to relevant successful development and approvals

Botanix Pharmaceuticals Ltd.

11

+

==> picture [79 x 27] intentionally omitted <==

BTX 1503 accelerated clinical development

Botanix is pursuing a rapid clinical development strategy to minimise product commercialisation timing and accelerate to first revenues

• First enrolment of Phase Ib acne pilot study expected to commenced in August 2017, with study data expected to be available in 4Q CY2017

• Botanix is fully funded for the Phase Ib clinical trial of BTX 1503, with potential further funding from Permetrex[TM ] licensing revenues

==> picture [639 x 187] intentionally omitted <==

----- Start of picture text -----

BTX 1503 indicative clinical timeline Q3 2017 Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 2018
Phase Ia acne pilot study
Phase Ib acne pilot study
FDA approval for Phase II trial
Phase II multi-centre acne patient trial
----- End of picture text -----

==> picture [20 x 23] intentionally omitted <==

Clinical milestones where potential development partnerships and/or licensing agreements may be considered

Botanix Pharmaceuticals Ltd.

12

+

==> picture [79 x 27] intentionally omitted <==

Clinical development pipeline

Development pipeline also includes other synthetic cannabidiol clinical products targeting key dermatology markets

BTX 1204: dermatitis

• Target market: US patient incidence estimated to be 31 million (10% to 18% of children)

BTX 1308: psoriasis

• Target market: 7.5 million Americans have psoriasis (most have plaque psoriasis)

==> picture [128 x 135] intentionally omitted <==

• Market size: estimated annual cost of treating atopic dermatitis in the US is ~US$4bn

▪ Market size: estimated annual costs of injectable biologic treatments in the US is ~US$20bn

• Current issues: most treatments ▪ Current issues: biologic drugs are on the market (i.e. steroids) only very expensive have serious side address the symptoms effect issues (including lymphoma)

These products will leverage both the BTX 1503 synthetic cannabidiol clinical program as well as the Permetrex[TM] delivery system

Psoriasis

==> picture [128 x 120] intentionally omitted <==

Dermatitis

Botanix Pharmaceuticals Ltd.

13

+

==> picture [79 x 27] intentionally omitted <==

Non-cannabidiol pipeline advancing quickly

Development pipeline includes a Permetrex[TM] enabled product with near term revenue potential - could be developed and marketed without FDA approval

Product overview

Indicative development timeline for BTX 1701

BTX 1701: acne cleanser

• Safety: Successful pilot human study completed, demonstrating a positive safety profile

Q2 2017 Q3 2017 Q4 2017 Q1 2018 Pilot study BTX1701 ✓ Commercial Review Patient study BTX 1701

• Efficacy: Pilot study validated prospective activity in removing skin oiliness and reducing bacteria

• Market size: for acne cleansers > US$1.5bn+ p.a.

• Botanix is reviewing multiple commercialisation strategies and will elect the option that delivers the highest shareholder value for the investment

• Potential for accelerated advancement as this product could be developed and marketed without FDA approval

==> picture [90 x 92] intentionally omitted <==

• Permetrex[TM] enabled formulation has competitive advantages over incumbent brands, many of which contain alcohol and preservatives that can actively dry out the skin and/or cause allergic reactions

Botanix Pharmaceuticals Ltd.

14

+

==> picture [79 x 27] intentionally omitted <==

Permetrex™ collaborations advancing

Third party dermatology companies working with Botanix to solve drug delivery problems for their molecules

Early collaborations leading to license discussions

• Many companies have challenges formulating drugs for delivery into the skin

• Botanix is working with multiple parties to test application of Permetrex™ technology to solve problems that have arisen in clinical studies

• Engagement generally starts as fee-forservice by Botanix

• License trigger is generally proof of concept human study

• Traditional license structure likely (upfront payments, milestones, royalties)

==> picture [268 x 297] intentionally omitted <==

Botanix Pharmaceuticals Ltd.

15

+

==> picture [79 x 27] intentionally omitted <==

Botanix key catalysts

Significant operational milestones expected over the next 9 months, as Botanix advances BTX 1503, broader pipeline and corporate development

==> picture [630 x 356] intentionally omitted <==

----- Start of picture text -----

Q3 Q4 Q1
Indicative activities and milestones
CY2017 CY2017 CY2018
Phase Ib acne patient pilot study
BTX 1503 FDA approval for Phase II trial
Phase II multi-centre acne patient study
Explore commercialisation opportunities
BTX 1701
Patient study BTX 1701
Study design and ethics approvals
BTX 1204
Phase 1b study in dermatitis patients
Research collaborations
Permetrex
Partnership discussions for Permetrex [TM] enabled
products
Milestones where potential licensing deals may be considered
----- End of picture text -----

Botanix Pharmaceuticals Ltd.

16

==> picture [139 x 540] intentionally omitted <==

+ Appendix

+

==> picture [79 x 27] intentionally omitted <==

Botanix Board of Directors

Highly credentialed Board of Directors with a proven record of building and leading successful pharmaceuticals businesses

==> picture [720 x 59] intentionally omitted <==

Graham Griffiths Chairman Appointed July 2016

Matthew Callahan Executive Director Appointed July 2016

Dr Bill Bosch Executive Director Appointed July 2016

Rob Towner Director Appointed July 2016

• 40 years executive experience in technology based companies, across sales, marketing and product development

• Former Managing Director of ipernica, responsible for acquisition and commercialisation of nearmap.com (ASX:NEA)

• Non-Executive Director of Pointerra (ASX:3DP), iperative and NGIS Australia

==> picture [25 x 16] intentionally omitted <==

Commercialisation

• Founding CEO of iCeutica and Churchill Pharmaceuticals

• Co-inventor of iCeutica’s SoluMatrix Technology

• Developed 3 FDA approved products

• Investment director at 2 venture capital firms

• 20 years experience in legal, IP and investment management

• Director of Orthocell (ASX:OCC) and Glycan Bioscience LLC

==> picture [26 x 16] intentionally omitted <==

Corporate and IP

• 20 years corporate advisory experience

• 20 years experience in the pharmaceutical industry

• Founder and sole director of Cornerstone Corporate

• Co-inventor of iCeutica’s SoluMatrix Technology

• Developed 6 FDA approved ▪ Founding Executive Director of products bioMD

• Developed 4 commercial ▪ bioMD merged with Allied nanotechnology products at Elan Health Care in 2011 to form Corporation Admedus (ASX:AHZ, $200m market capitalisation)

• Co-founder of NanoSystems LLC and co-inventor of NanoCrystal Technology

• Executive Director of Triangle Energy (ASX:TEG)

==> picture [26 x 15] intentionally omitted <==

==> picture [25 x 16] intentionally omitted <==

Manufacturing and IP

Financing and capital markets

Botanix Pharmaceuticals Ltd.

18

+

==> picture [79 x 27] intentionally omitted <==

Botanix executive management

Highly credentialed clinical development team with extensive expertise in leading novel products through clinical and regulatory development

Mr Mark Davis VP Clinical and Regulatory

Dr Michael Thurn Chief Operating Officer

• 30 years of clinical experience with 19 ▪ Extensive start up life sciences FDA approved products experience across a range of technology

• ▪ Unique experience with cannabidiol platforms

• Unique experience with cannabidiol through Insys

• +20 years experience in drug regulation, drug discovery, pre-clinical and clinical

• Former clinical lead with Medicis and Connetics

• Previous Managing Director of Spinifex Pharmaceuticals

Clinical and regulatory

Regulatory and operations

Dr Gene Cooper Consultant

• 40 years pharmaceutical experience

• 10 FDA approved products

• Expert in skin delivery

• Inventor of Permetrex™

Technology and innovation

Dr Joel Gelfand Professor James Medical Director Leyden of Clinical Studies Scientific Adviser

Professor Diane Thiboutot Scientific Adviser

• Professor of Dermatology at the University of Pennsylvania

• Expert in skin disease and clinical trial management

• Professor of Dermatology at the University of Pennsylvania

• ▪ World leading acne and skin specialist

• Professor of Dermatology at Pennsylvania State University

• ▪ Researcher in acne and rosacea ▪ Pre-clinical and clinical trials services provider

Clinical Studies

Key Opinion Leader

Key Opinion Leader

Botanix Pharmaceuticals Ltd.

19

+

==> picture [79 x 27] intentionally omitted <==

Strategic and commercialisation focus

Primary strategy is commercialising BTX 1503, with a supportive pipeline of other medical dermatology products and opportunities for near term revenue generation

==> picture [624 x 224] intentionally omitted <==

----- Start of picture text -----

Active pharmaceutical
Cannabidiol
Botanix product
BTX 1503 BTX 1701 Permetrex [TM] BTX 1308 BTX 1204
Clinical application Delivery technology
Acne Acne cleanser Psoriasis Dermatitis
Near term focus Near to medium term focus Medium to long term focus
BTX 1503 development and
Permetrex [TM] licensing Other pipeline products
commercialisation
----- End of picture text -----

Accelerating clinical development Licensing Permetrex[TM] delivery system through undertaking low cost clinical to strategic parties, to generate studies in Australia, feeding into a US FDA potential near term revenue approval

Development of an acne cleanser, that can be developed without FDA approval , in order to generate near term revenue

Leverage data from BTX 1503 program to accelerate development of new products in psoriasis and dermatitis and other products may not require FDA approval

Botanix Pharmaceuticals Ltd.

20

+

==> picture [79 x 27] intentionally omitted <==

Recent corporate and product development

Recent corporate developments have provided a strong platform for Botanix to accelerate its clinical development program

Corporate milestones

Mar 2016

Jul 2016

Pre-RTO: Bone Completed RTO and Medical announce commencement of reverse take over trading as Botanix (RTO) by Botanix Pharmaceuticals Pharmaceuticals (ASX:BOT)

Jul 2016 to Feb 2017

Key staff hires across the business divisions of clinical and regulatory, manufacturing, toxicology and operations

Feb 2017

Completed expansion of Permetrex™ license to cover the delivery of all drug actives used in treating skin diseases

Mar 2017

Mar 2017 Apr 2017 Received DEA approval Completed for export and import A$7.4million of synthetic cannabidiol oversubscribed for planned clinical placement studies

==> picture [720 x 56] intentionally omitted <==

Development milestones

Nov 2016

Jul 2016

Secured access to Manufactured BTX commercial scale 1503 trial formulation synthetic using FDA quality cannabidiol components

Dec 2016

Completed first human safety and irritation study with Permetrex[TM]

Mar 2017

Received HREC approval for BTX 1503 clinical studies, and commenced first clinical study

June 2017 July 2017 Completion of Successful completion of successful pilot Phase 1 clinical study for study for BTX 1701 BTX 1503 facial cleanser

Formulation

Confirm Permetrex[TM] Safety

Proof of Concept

Key milestones achieved

Botanix Pharmaceuticals Ltd.

21

+

==> picture [79 x 27] intentionally omitted <==

Accelerated development timeline

Botanix is executing on an efficient, more economical and less risky clinical development strategy compared to traditional pharmaceutical development pathways

Botanix’s accelerated clinical timeline

Proven ability to execute: Achieved since listing

Proven ability to execute:Achieved since listing	Proven ability to execute:Achieved since listing	Proven ability to execute:Achieved since listing	Proven ability to execute:Achieved since listing	Proven ability to execute:Achieved since listing
Phases			Botanix approach Costs (est.) Timing (est.) ~$1m ~6 months
	Traditional process
	Costs (est.)	Timing (est.)	Costs (est.)
Discovery and pre-clinical	~$430m	~5 years	~$1m
Investigational New Drug filing	~$1m
Phase I clinical	~$25m	~7 years
			~$2m	~6 months ~28 months ~12 months ~4 years
Phase II clinical	~$35m		~$5m
Phase III clinical	~$54m		~$20m
New Drug Application	~$5m	~2 years	~$2m
Total	~$460m	~14 years	~$30m

• Accelerated development timeline, due to:

• Minimal pre-clinical development due to known safety profile of cannabidiol

• Dermatology studies tend to be shorter in duration and require smaller study populations

• Objective measurements of efficacy (end points are typically visual assessments)

• Opportunity to generate near term revenue from potential licensing agreements for Permetrex[TM]

• In house expertise ensures clinical trials are appropriately designed and efficiently implemented

• Known safety profile increases probability of successful clinical development

Botanix Pharmaceuticals Ltd.

22

+

==> picture [79 x 27] intentionally omitted <==

Commercialisation strategy

Botanix’s focused and accelerated timeline to product commercialisation results in significant potential value uplift

Efficient commercialisation path with multiple options

Value uplift

• Continued clinical development success is reflected in significant value uplift after each successive phase

• Typically monetised via licensing, partnering and/or sale/merger opportunities

• Additional indications can be partnered while pursuing acne focus

• Potential future revenue streams:

• Product licensing agreements

• Partnership with strategic parties

• Product sales revenue

==> picture [368 x 259] intentionally omitted <==

----- Start of picture text -----

Significant value uplift potential at the
completion of each phase of development
(as evidenced by recent dermatology
Phase 3
transactions)
(~ 24 months)
Phase 2
(~ 12 months)
Phase 1
Investment decision
(< 12 months)
License, partner and/or
sale opportunities
----- End of picture text -----

==> picture [37 x 11] intentionally omitted <==

----- Start of picture text -----

Time
----- End of picture text -----

Botanix Pharmaceuticals Ltd.

23

+

==> picture [79 x 27] intentionally omitted <==

Valuable intellectual property portfolio

Botanix has protected its suit of development products through various patent applications across key global markets

• Botanix currently has 12 patent applications across 6 different patent families

• Patents applications cover lead acne product and other Permetrex[TM] enabled products

• Patent protection targeted at key geographic regions with large and viable dermatology markets (i.e. initially filed in US and Australia, but following into the EU, UK, Japan, India, China, South America and other jurisdictions in National phase)

• Botanix positioned as the leading player in the sector – underpinned by substantial volumes of proprietary knowledge, manufacturing know-how and trade secrets

• Additional IP opportunities will be pursued on each Permetrex[TM] product developed internally or with partners

==> picture [377 x 297] intentionally omitted <==

----- Start of picture text -----

Expanded patent applications for
BTX 1503 and other Permetrex [TM]
enabled products
Initial patent applications protecting
BTX 1503
----- End of picture text -----

Botanix Pharmaceuticals Ltd.

24

+

==> picture [79 x 27] intentionally omitted <==

Recent dermatology transactions

Licensing and partnering transactions are potential monetisation options before product sales, with value increasing significantly as a product progress through the FDA process Dermatology transactions

==> picture [664 x 334] intentionally omitted <==

----- Start of picture text -----

US$5,200m
Licensing deals
US$790m Total upfront and US$770m
milestone payments US$639m
could exceed these
US$445m figures in aggregate
US$150m
US$90m
Deal date Sep 15 Dec 2016 Jan 2016 Dec 2016 Oct 2016 Apr 2016 May 2016
Deal type License License Corporate Corporate Corporate Asset/business Corporate
Licensee/Acquirer Allergan
Licensor/Target
(global dermatology
(rights) business)
In pre-clinical
In pre-clinical
Phase In Phase III Completed Phase I development / In Phase II On market Completing Phase III
development
Phase IIb
----- End of picture text -----

Source: Bloomberg, Company disclosure

Botanix Pharmaceuticals Ltd.

25

+

==> picture [79 x 27] intentionally omitted <==

International landscape

Botanix represents a significant value accretive opportunity when compared to key global peers with positive Phase I and Phase II data

Market capitalisation of key international peers[1]

Zynerba share price performance (US$)

==> picture [652 x 308] intentionally omitted <==

----- Start of picture text -----

24
US$1.2bn
Announced positive
20 ZYN002 Phase I
results
16
US$0.3bn
US$0.2bn 12
US$0.1bn
8
Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17
Novan Zynerba Cassiopea Dermira
Dermatology focused ✓ ✓ ✓ Dermira share price performance (US$)
Cannabidiol ✓ 28
focused
Announced positive
24
No. of DRM01 Phase II
Multiple Multiple Multiple Multiple
products results
20
Glycopyrronium
SB206: II Winlevi©:III
Clinical ZYN002 CBD Gel: II Tosylate:III 16
SB208: II Breezula©:III
development SB414: I ZYN001 THC Pro- CB-06-01: II CIMZIA©:III
phase SB414: I Drug Patch: I CB-06-02: II Olumacostat Glasaretil:III 12
Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15
----- End of picture text -----

Source: Bloomberg, Company disclosure 1. Market capitalisation figures as at close 6 July 2017

Botanix Pharmaceuticals Ltd.

26

+

==> picture [79 x 27] intentionally omitted <==

Disclaimer

This presentation prepared by Botanix Pharmaceuticals Limited (" Company ") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) forany information, representation or statement made in or omitted from this presentation.

This document contains certain forward looking statements which involve known and unknown risks, delays and uncertainties not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forwardlooking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Botanix Pharmaceuticals Ltd.

27